Beauitiful... Now that is cleared up..... do you think that there is a difference in being able to detect diseases with "lack of" or "overproduction of" MANF as a signal of disease pathology and the patients that AMBS has on MANF. In other words, if MANF is naturally occurring in the body and they are using it as a marker of disease, do you think that applies to the AMBS patient? Would Roche have to give some sort of compensation to AMBS. Is the patent that far reaching, in that, anything related to MANF for treatment or diagnosis is covered under that patent? Yes I know.....bunch of the same questions phrased differently. In other words......why would Roche have to compensate AMBS? If the tick up on friday was due to this, why no follow through today? Would this not be monumental news? A Major pharma having to compensate Amarantus? Thoughts?